Mobile website
Review
Progress of nanocarrier based on the CD47 peptide-mediated "stealth" strategy in cancer therapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Nanocarriers are prone to rapid clearance by the mononuclear phagocyte system (MPS) in tumor-targeted therapy, leading to reduced drug bioavailability and limited anti-tumor efficacy. The CD47 peptide-mediated "stealth" strategy, by mimicking the "don't eat me" signal, can effectively inhibit macrophage phagocytosis of nanocarriers, serving as an effective means to prolong the in vivo circulation half-life of drugs and enhance tumor-targeted delivery efficiency. This review summarizes the mechanism of action, carrier types, major application progress, key challenges, and potential solutions of the CD47 peptide "stealth" strategy. It focuses on the structure-activity relationship of CD47 peptide modification, the applicability differences of different nanocarrier platforms, research gaps in long-term delivery efficiency and in vivo stability, as well as the construction of standardized evaluation systems and future development directions. The goal is to promote CD47 peptide-modified nanocarriers as an important stealth-capable platform for precision tumor delivery, providing new strategies for improving the in vivo delivery efficiency and anti-tumor efficacy of nanomedicines.
Keywords:
Project Supported:
Clc Number:
